Keryx Biopharmaceuticals (KERX +0.00%) stunned the market yesterday after releasing positive phase 3 data for its hyperphosphatemia drug Zerenex. Shares jumped around 75% after the news was released, and investors are still enjoying the newfound optimism surrounding this biotech company. Shares hopped another 40% today, but what caused this additional jump? What should investors watch for going forward? In this video, health care analyst Max Macaluso dives into these questions.
Can Keryx Continue Climbing?
By Max Macaluso – Jan 29, 2013 at 2:36PM
NASDAQ: KERX
Keryx Biopharmaceuticals
After yesterday's jump, why is Keryx still on a roll?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo